Pay in 4 interest-free payments of $5.55 Learn more
Ships within 48 hours · Estimated delivery Aug 12 - Aug 17
Guidelines for patient appointments and follow-ups, including pre-appointment questionnaires
CAS Number 2023788-19-2 Molecular Weight 4813.45 g/mol Molecular Formula CHNO Class Dual GIP/GLP-1 Receptor Agonist Research context
Once improved metabolic parameters were established after RETA treatment, we assessed the impact of RETA on LUAD
The most frequently reported adverse effects relate to the gastrointestinal system rather than direct cardiac effects, including nausea (occurring in approximately 15-20% of patients according to the SmPC), vomiting, diarrhoea, and constipation
US$ 27.71
US$ 23.61
US$ 20.15
US$ 24.75
:max_bytes(150000):strip_icc()/VWH-WegovyPill-d9a4977443014c7cbc6d2bad906b9098.jpeg)
US$ 28.63
